We serve Chemical Name:3-(Trifluoromethyl)benzoyl fluoride CAS:328-99-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Trifluoromethyl)benzoyl fluoride
CAS.NO:328-99-4
Synonyms:EINECS 206-340-8;MFCD00018047;3-(trifluoromethyl)benzoyl fluoride;m-trifluoromethylbenzoyl fluoride
Molecular Formula:C8H4F4O
Molecular Weight:192.11000
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:172.3ºC at 760mmHg
Density:1.339g/cm3
Index of Refraction:1.4341
PSA:17.07000
Exact Mass:192.02000
LogP:2.81510
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3265
Packing Group:
Contact us for information like EINECS 206-340-8 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,m-trifluoromethylbenzoyl fluoride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 206-340-8 Use and application,EINECS 206-340-8 technical grade,usp/ep/jp grade.
Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 3-(Trifluoromethyl)benzoyl fluoride manufacturer The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination. 3-(Trifluoromethyl)benzoyl fluoride supplier Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 3-(Trifluoromethyl)benzoyl fluoride vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 3-(Trifluoromethyl)benzoyl fluoride factory The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.
